certolizumab,golimumab,infliximab,adalimumab,natalizumab,vedolizumab,ustekinumab
ucb pharmaceuticals,takeda,janssen,biogen,abbvie
['vedolizumab', 'certolizumab', 'natalizumab', 'golimumab', 'vedo', 'ustekinumab', 'adalimumab', ' vedo', 'crohn', 'ulcerative colitis', 'ibd', 'infliximab']
biologic use and gastrointestinal infection risk in ibd risk of non-cdiff gi infections in antitnf risk in cdiff for anti-integrin but risk of non-cmv gi viral infections 2000-2021 retrospective brilliant work #ddw2023 #agalive2023 #ibd 
Celebrate life. Gastroenterologist #IBD passionate. Help others grow their abilities. https://t.co/4V0xhhdIti